Spots Global Cancer Trial Database for advanced stage
Every month we try and update this database with for advanced stage cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % | NCT04547504 | Non-small-cell ... | Pembrolizumab Pembrolizumab a... | 18 Years - | University Hospital, Brest | |
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma | NCT00201838 | Pancreatic Neop... Adenocarcinoma | Gemcitabine Etanercept | 18 Years - | Ohio State University Comprehensive Cancer Center | |
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % | NCT04547504 | Non-small-cell ... | Pembrolizumab Pembrolizumab a... | 18 Years - | University Hospital, Brest | |
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC | NCT05332821 | Hepatocellular ... | PD-1/PD-L1 inhi... TACE | 18 Years - | Zhongda Hospital | |
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. | NCT01291017 | Non-small Cell ... | PD0332991 | 18 Years - | University of Florida | |
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE) | NCT05049044 | Non-Small Cell ... | Quality of Life... | 18 Years - | Groupe Francais De Pneumo-Cancerologie | |
Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer | NCT00283478 | Non-Small Cell ... | Iscar Quercus Gemcitabine | 18 Years - | Kentuckiana Cancer Institute | |
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma | NCT00535951 | Carcinoma, Non-... Mesothelioma | LBH589 | 18 Years - | Novartis | |
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma | NCT00201838 | Pancreatic Neop... Adenocarcinoma | Gemcitabine Etanercept | 18 Years - | Ohio State University Comprehensive Cancer Center | |
PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % | NCT04547504 | Non-small-cell ... | Pembrolizumab Pembrolizumab a... | 18 Years - | University Hospital, Brest | |
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma | NCT00201838 | Pancreatic Neop... Adenocarcinoma | Gemcitabine Etanercept | 18 Years - | Ohio State University Comprehensive Cancer Center | |
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE) | NCT05049044 | Non-Small Cell ... | Quality of Life... | 18 Years - | Groupe Francais De Pneumo-Cancerologie | |
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC | NCT01156545 | Non-small Cell ... | BIBW 2992 simvastatin | 18 Years - | National Cancer Center, Korea | |
First-line Combination Treatment Based on Anlotinib | NCT03628521 | Lung Cancer Advanced Stage | Anlotinib,Erlot... | 18 Years - 75 Years | Shanghai Chest Hospital |